<<
>>

tsitoprotektornaja ACTIVITY LIKOPIDA AND STANDARD THERAPY

10 children are included in research with a jet arthritis at the age of 6-15 years (middle age 11,3+0,6 years), among which 6 boys and 4 girls. Duration of the basic disease varied from 5 months till 3 years.

All children it is out-patient accepted diklofenak Na in a daily dose of 2-3 mg/kg from 4 till 6 weeks. The characteristic of patients is presented in tables 19 and 20.

Pains, a various degree of manifestation and localisation, were observed at 5 children (a mean score - 3,4±0,73). "JAzvennopodobnyj" the pain syndrome is noted at 1 child, "gastritopodobnyj" - at 4 patients. Half of patients did not show the complaint to a pain syndrome. At 60 % of children the symptom stomachal dispepsii is revealed: the heartburn took place at 3 patients (a mean score - 3,2±0,7), an eructation and meteorizm observed at 3 and 4 accordingly (a mean score 1.8+0,4 and 1,2±0,5 accordingly). Complaints on

9

The nausea was shown by 4 patients. Vomiting was marked at 2 patients. Chair distress (propensity to locks) took place at 4 children.

At endoskopicheskom research at 20 % of patients it is revealed fundalnyj a gastritis and at 50 % - antralnyj or pangastrit, at 10 % a reflux - a gastritis, at 20 % of children erozivnyj a gastritis. The phenomena bulbita are fixed at 40 % of patients, diffusive duodenita at 30 % and erozivnogo duodenita - at 10 %.

In addition to antibiotics and diklofenaku sodium the patient of the given bunch appointed likopid per os within 21 days.

Frequency of revealing of intensity of the basic clinical exhibitings in the course of treatment are presented in table 23

Table 23

Dynamics of symptoms gastropatii in the course of treatment likopidom

Pain Heartburn Eructation meteorizm Nausea | IKL
Initially 3,4+0,7 3,2±0,7 1,8+0,4 1,2+0,5 1,0±0,5 1 10,6±1,4
7 day 2,2±0,8 2,4±0,5 0,6±0,4 0,8±0,4 0,8±0,4 ' 6,8±0,9*
21 day 1,4±0,3* 1,0±0.3* 0,2±0,2* 0,4+0,3 0.6+0.3 (3.6±0.6*

The note: see table 21.

By the end of the first week of treatment of a pain in a gaste have not disappeared at one child, but their intensity have considerably decreased. In 3 weeks

g

Supervision full knocking over of a pain syndrome is noted at 2 children from 5, at the others - its intensity has essential decreased. Intensity dispepsii has decreased in 7 days and is completely stopped by 21 day at 2 of 6 children. About a quarter of patients have kept some clinical exhibitings (a heartburn, meteorizm, a nausea) it is considerable smaller expressiveness. IKA for 1 week has decreased with 10,6± 1,4 only to 6,8±0,9 points and for 21 day - to 4,6±0,6 points (on 56,6 %). By the end of a course of therapy excellent results are noted at 3 patients; good and satisfactory at 6 patients and at 1 child the unsatisfactory result is fixed.

On given endoskopii reduction of the phenomena of an inflammation in a mucosa of an esophagus, a stomach and 12-perstnoj guts (reduction of a hypostasis, a hyperemia mucous, healing of erosion) at 50 % of patients is noted. IEA by the treatment end has decreased with 5,8+ОД to 3,3+0,3 points (43,2 %). At half of children of erosion have disappeared completely, at half - their quantity has decreased.

Therapy likopidom was a little less effective at patients with medicinal gastropatijami though the preparation was well tolerated and did not invoke, behind an exception subfebriliteta, side reactions.

Results of the spent researches testify to ability immunomodulirujushchih preparations to render reparativnoe action and to reduce clinical and endoskopicheskie signs НГІВІ 1-gastropatii. In efficacyy derinat surpassed preperat comparisons likopid, but conceded reference protivojazvennomu to a preparation - omeprazolu. Gastroprotektornyj the effect derinata in the accessible literature is bound as with direct reparativnym action nativnoj DNA (Romashkina T.S. and soavt., 2000), and with ability of a preparation to normalise the broken exchange of nucleotides in the field of ulcer defect (Koltsov P. A, 1991). But in our opinion, a certain role in realisation гасіропротскторного effect play property joint-stock company derinata (Kaplina E.N., Vajnberg J.V., 2004) and ability of a preparation to stabilise lipidnyj structure of cellular membranes at the expense of activity decrease fosfoliiidazy? \2 (Vlasov A.P., 2004). Important value has also ability IT of preparations at the expense of normalisation of factors of nonspecific protection and indicators of cellular immunodefence, to raise efficacyy eradikatsionnoj therapies (Zodiochenko A.V. and soavt., 1990). Obviously, less expressed tsitoprotsktornyj the effect likopida is caused by presence in the mechanism of its action only the last (immunomodulirujushchego) and as consequence of an anti-inflammatory component whereas derinat possesses the whole complex of effects beneficial in this case - antioksidantnym, metabolic, reparativnym.

<< | >>
Scientific source RODIONOVA SVETLANA VIKTOROVNA. STUDYING of EFFICACYY of IMMUNOMODULATING FACTOR DERINATA In TREATMENT of CHRONIC JET ARTHRITISES HLAMIDIJNOJ of the ETIOLOGY At CHILDREN. The DISSERTATION on competition of a scientific degree of the candidate of medical sciences. Saransk 2007 . 2007

Other medical related information tsitoprotektornaja ACTIVITY LIKOPIDA AND STANDARD THERAPY:

  1. Chapter 4 Discussion of the received results
  2. Chapter 7. The PROGRAM CONCEPT «CHRONIC HEPATITISES At CHILDREN And TEENAGERS»
  3. APPENDICES
  4. design of research, criteria of including and an exception, grouping surveyed
  5. an anaemia at standard methods of therapy juvenilnogo a pseudorheumatism
  6. 3.5. An estimation of dynamics of average concentration of haemoglobin at children with JURA, receiving various variants of therapy
  7. modern representation about an aetiology and a pathogenesis of an acute stenosing laryngitis (croup) at children
  8. CHAPTER 4. ACTIVE PRIMARY GERPESVIRUSNAJA THE INFECTION AT CHILDREN WITH THE LONG SUBFEBRILE CONDITION
  9. 7.1 Clinical characteristic of patients active primary GVI after treatment.
  10. Chapter 2. MATERIALS And METHODS.
  11. Chapter 3.1. Efficiency and safety infliksimaba at children with JUIA.
  12. Chapter 3.2. Efficiency and safety etanertsepta at children with JUIA.
  13. Chapter 3.3. Efficiency and safety abatatsepta at children with JUIA.
  14. the Bronchial asthma and mechanisms of protection of organs of breath from adverse influences
  15. an aetiology and a pathogenesis of disorders of an emiction.